For the quarter ending 2026-03-31, SLNCF had -$5,603K decrease in cash & cash equivalents over the period. -$15,603K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Revenue | -103 | - | - |
| Cost of sales | -192 | - | - |
| General and administrative expenses | -11,584 | - | - |
| Tax expense | -11 | - | - |
| Net loss | -14,957 | -11,770 | -76,842 |
| Depreciation expense | 72 | 77 | 235 |
| Amortization expense | 34 | 36 | 207 |
| Share-based compensation expense | 2,447 | -86 | 8,160 |
| Net foreign exchange impacts | 25 | -230 | -10,792 |
| Other income, net | 519 | 880 | 2,600 |
| Income tax expense | - | 0 | 11 |
| Decrease in trade receivables | 0 | -30 | -994 |
| Decrease/(increase) in other current assets | -931 | 1,741 | -7,757 |
| (increase)/decrease in r&d benefit receivable | 209 | -190 | -3,851 |
| Decrease in other long-term assets | 0 | -257 | -3,401 |
| (decrease)/increase in trade and other payables | -2,949 | -3,576 | -502 |
| Increase in contract liabilities | -404 | -32 | -302 |
| Increase in operating lease liabilities | -24 | -22 | -146 |
| Net cash used in operations | -15,603 | -17,287 | -44,984 |
| Redemption of term deposits | 74,427 | 20,440 | 98,036 |
| Purchase of term deposits | 64,427 | 73,778 | 92,635 |
| Purchase of property, plant and equipment | 0 | 0 | 55 |
| Net cash provided by/(used in) investing activities | 10,000 | -53,338 | 5,346 |
| Proceeds from issue of ordinary shares | 0 | 0 | 15 |
| Net cash provided by financing activities | 0 | 0 | 15 |
| Decrease in cash and cash equivalents | -5,603 | -70,625 | -39,623 |
| Cash and cash equivalents at start of period | 11,277 | 0 | 121,330 |
| Effect of exchange rate fluctuations on cash and cash equivalents held | -17 | -129 | 324 |
| Cash and cash equivalents, end of period | 5,657 | 11,277 | 82,031 |
Silence Therapeutics plc (SLNCF)
Silence Therapeutics plc (SLNCF)